[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552743":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":24,"responsibleParty":56,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":10,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort 1",null,"consists of 30 patients who experienced a recurrence more than 6 months after completing 3 years of adjuvant osimertinib.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort 2","consists of 30 patients with recurrence during adjuvant osimertinib treatment.",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Yongchang Zhang, MD","CONTACT","13873123436","zhangyongchang@csu.edu.cn",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":10},"Liang Zeng, MD","15974139200",[25,41],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Hunan Provincal Tumor Hospital","RECRUITING","Changsha","Hunan","410013","China","CN",{"type":34,"coordinates":35},"Point",[36,37],112.97087,28.19874,{"lat":37,"lon":36},[40],{"name":17,"role":18,"phone":19,"phoneExt":19,"email":20},{"facility":42,"status":27,"city":43,"state":44,"zip":45,"country":31,"countryCode":32,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"The Second Affiliated Hospital Zhejiang University School of Medicine","Hangzhou","Zhejiang","310009",{"type":34,"coordinates":47},[48,49],120.16142,30.29365,{"lat":49,"lon":48},[52],{"name":53,"role":18,"phone":54,"phoneExt":54,"email":55},"Yang Xia, MD","18868439669","yxia@zju.edu.cn",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yongchang Zhang","Professor","100552743","the-recurrence-gene-profiles-of-adjuvant-osimertinib-therapy-in-resected-non-small-cell-lung-cancer-100552743",false,"NCT06477055","The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer","A Multicenter, Real-World, Observational Study: Genomic Landscape of Recurrence in Early-Stage (Clinical Stage IB-IIIA) Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Sensitizing Mutations After Adjuvant Osimertinib Treatment","RAISE","Inclusion Criteria:\n\n1. Informed consent signed;\n2. Age ≥ 18 years;\n3. Histologically confirmed diagnosis of non-squamous non-small cell lung cancer;\n4. Patients with stage IB-IIIA (TNM 8#) NSCLC undergo confirmed radical R0 resection;\n5. Confirmed EGFR sensitive-mutations (exon 19 deletions, 21 L858R point mutations) prior to adjuvant osimertinib therapy;\n6. Recurrence after\u002Fon Osimertinib treatment according to RECIST 1.1;\n7. NGS gene test report (tumor or blood sample) at the time of recurrence;\n8. Receiving or not receiving neoadjuvant treatment before surgery.\n\nExclusion Criteria:\n\n1. Patients with stage I-III NSCLC whose surgical resection cannot be confirmed;\n2. Received adjuvant therapy other than that specified in the ADAURA study;\n3. No NGS test report at recurrence;\n4. History of other malignant tumors within 2 years;\n5. Patients assessed by the investigator as unfit for enrollment, such as neurological disorders or metabolic disorders, physical examination or laboratory examination suspected that the patient has a possible disease, or has treatment-related complications High risk etc.","ALL",{"count":70,"type":71},60,"ESTIMATED","OBSERVATIONAL","This study was a multicenter, real-world observational study aimed at characterizing the genomic landscape of recurrence in patients with EGFR-sensitizing mutation-positive early-stage (clinical stage IB-IIIA) non-small cell lung cancer who received adjuvant osimertinib after surgery.",[75],"Non-small Cell Lung Cancer",[77,78],"EGFR","Osimertinib","2026-04-08",{"date":81,"type":82},"2026-04-13","ACTUAL",{"date":84,"type":82},"2025-12-02",{"date":86,"type":71},"2026-04-30",{"name":5,"class":6},2]